Connect Biopharma Holdings Future Growth
Future criteria checks 1/6
Connect Biopharma Holdings's earnings are forecast to decline at 15.9% per annum while its annual revenue is expected to grow at 14.3% per year. EPS is expected to decline by 0.3% per annum.
Key information
-15.9%
Earnings growth rate
-0.3%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 14.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 06 Sep 2024 |
Recent future growth updates
Recent updates
Connect Biopharma Holdings (NASDAQ:CNTB) Is In A Strong Position To Grow Its Business
Sep 27
Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Are In A Position To Invest In Growth
Mar 07Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth?
Sep 19Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
Mar 29Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Deliver On Growth Plans?
Dec 14Market Appears To Relegate Connect Biopharma To A Long-Term Hold
Oct 10Connect Biopharma Is A Sleeper Heading Into October Data Readout
Sep 26Connect Biopharma reports 1H results
Sep 13We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Aug 12We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Apr 29Connect Biopharma's Latest Dermatitis Drug Update Fails To Pump Up Shares
Jan 12We're Hopeful That Connect Biopharma Holdings (NASDAQ:CNTB) Will Use Its Cash Wisely
Jan 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 18 | -51 | N/A | N/A | 2 |
| 12/31/2025 | 30 | -31 | N/A | N/A | 2 |
| 12/31/2024 | 24 | -11 | N/A | N/A | 1 |
| 6/30/2024 | 24 | -21 | -25 | -25 | N/A |
| 3/31/2024 | 12 | -40 | -37 | -36 | N/A |
| 12/31/2023 | N/A | -60 | -48 | -48 | N/A |
| 9/30/2023 | N/A | -77 | -69 | -67 | N/A |
| 6/30/2023 | N/A | -93 | -89 | -85 | N/A |
| 3/31/2023 | N/A | -104 | -96 | -92 | N/A |
| 12/31/2022 | N/A | -118 | -106 | -102 | N/A |
| 9/30/2022 | N/A | -131 | -107 | -103 | N/A |
| 6/30/2022 | N/A | -114 | -97 | -95 | N/A |
| 3/31/2022 | N/A | -163 | -96 | -93 | N/A |
| 1/1/2022 | N/A | -202 | -88 | -84 | N/A |
| 9/30/2021 | N/A | -229 | -76 | -71 | N/A |
| 6/30/2021 | N/A | -255 | -63 | -57 | N/A |
| 3/31/2021 | N/A | -185 | -45 | -41 | N/A |
| 12/31/2020 | N/A | -119 | -28 | -26 | N/A |
| 12/31/2019 | N/A | -24 | -13 | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNTB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNTB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNTB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNTB's revenue (14.3% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: CNTB's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNTB's Return on Equity is forecast to be high in 3 years time